Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Comparison of Progression of Drusen in Eyes with Macular Neovascularization versus Geographic Atrophy in Eyes with Age-related Macular Degeneration
Parsa Riazi Esfahani; Akshay Reddy; Nathaniel Tak; Ziyuan Chris Wang; SriniVas R Sadda; Zhihong Hu
Author Affiliations & Notes
  • Parsa Riazi Esfahani
    Doheny Image Analysis Laboratory, Doheny Eye Institute, Los Angeles, California, United States
  • Akshay Reddy
    Doheny Image Analysis Laboratory, Doheny Eye Institute, Los Angeles, California, United States
  • Nathaniel Tak
    Doheny Image Analysis Laboratory, Doheny Eye Institute, Los Angeles, California, United States
  • Ziyuan Chris Wang
    Doheny Image Analysis Laboratory, Doheny Eye Institute, Los Angeles, California, United States
  • SriniVas R Sadda
    Doheny Image Analysis Laboratory, Doheny Eye Institute, Los Angeles, California, United States
  • Zhihong Hu
    Doheny Image Analysis Laboratory, Doheny Eye Institute, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Parsa Riazi Esfahani None; Akshay Reddy None; Nathaniel Tak None; Ziyuan Wang None; SriniVas Sadda 4DMT, Abbvie, Alexion, Allergan Inc., Alnylam Pharmaceuticals, Amgen Inc., Apellis Pharmaceuticals, Inc., Astellas, Bayer Healthcare Pharmaceuticals, Biogen MA Inc., Boehringer Ingelheim, Carl Zeiss Meditec, Catalyst Pharmaceuticals Inc., Centervue Inc., GENENTECH, Gyroscope Therapeutics, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Janssen Pharmaceuticals Inc., Nanoscope, Notal Vision Inc., Novartis Pharma AG, Optos Inc., Oxurion/Thrombogenics, Oyster Point Pharma, Regeneron Pharmaceuticals Inc., Samsung Bioepis, Topcon Medical Systems Inc., Code C (Consultant/Contractor), Carl Zeiss Meditec, Heidelberg Engineering, Optos Inc., Nidek, Topcon, Centervue, Code F (Financial Support), Carl Zeiss Meditec, Heidelberg Engineering, Nidek Incorporated, Novartis Pharma AG, Topcon Medical Systems Inc., Code R (Recipient); Zhihong Hu None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2293. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Comparison of Progression of Drusen in Eyes with Macular Neovascularization versus Geographic Atrophy in Eyes with Age-related Macular Degeneration
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Parsa Riazi Esfahani, Akshay Reddy, Nathaniel Tak, Ziyuan Chris Wang, SriniVas R Sadda, Zhihong Hu; Comparison of Progression of Drusen in Eyes with Macular Neovascularization versus Geographic Atrophy in Eyes with Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2293.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : Drusen is a hallmark feature of early and intermediate age-related macular degeneration (AMD). Still, the outcome and progression of drusen in the late stages of AMD (macular neovascularization (MNV) or geographic atrophy (GA)) is not well understood. This study compares quantitative drusen characteristics over time in eyes with MNV versus GA.

Methods : Color fundus photographic (CFP) data from 30 eyes with MNV and 30 eyes with GA from the Age-Related Eye Disease Study (AREDS) dataset were utilized for this pilot longitudinal analysis. The analysis spanned three time points: baseline, 4 years, and 8 years. A machine-learning algorithm, specifically a U-net model, was developed alongside a manual grading process utilizing labeling software to quantify the number of drusen and determine the total area of drusen in each image.

Results : At the 8-year mark, a statistically significant difference in the number of drusen was observed using unpaired t-test in eyes with MNV (68.9 ± 43.1) compared to those with GA (46.2 ± 28.2, p = 0.02). However, at the baseline and 4-year timelines, no significant differences in the number of drusen were noted between the two groups. Furthermore, the total area of drusen exhibited a significant increase utilizing paired t-test in patients with MNV at the 8-year mark (1589.6 ± 1207.3 pixels) compared to baseline (1051.0 ± 973.4 pixels, p = 0.01).

Conclusions : This pilot analysis highlights the difference in drusen burden and evolution over time in eyes with GA vs MNV. Drusen area appears to increase over time in eyes with MNV and appears to be significantly greater in eyes with MNV compared with GA. Understanding these nuances in disease progression is crucial for developing targeted interventions and personalized treatment strategies for AMD patients. The mechanisms underlying these differences warrant further study.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

Figure 1. Disease Progression in NV and GA in AMD.
View OriginalDownload Slide

Figure 1. Disease Progression in NV and GA in AMD.

Figure 1. Disease Progression in NV and GA in AMD.

Figure 1. Disease Progression in NV and GA in AMD.
View OriginalDownload Slide

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept